GO
Loading...

Enter multiple symbols separated by commas

Mergers and Acquisitions Takeover Bids

More

  • Pfizer, AstraZeneca about drug pipeline: Pro Monday, 28 Apr 2014 | 11:23 AM ET
    Pfizer, AstraZeneca about drug pipeline: Pro

    Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.

  • Pfizer pushes for $100 billion AstraZeneca deal Monday, 28 Apr 2014 | 10:10 AM ET
    Pfizer pushes for $100 billion AstraZeneca deal

    Pfizer is working on its next move in a potential $100 billion battle for AstraZeneca after having two bids rejected. CNBC's Meg Tirrell reports buying AstraZeneca would boost Pfizer's cancer drug pipeline.

  • AstraZeneca not a great company: Cramer Monday, 28 Apr 2014 | 9:01 AM ET
    AstraZeneca not a great company: Cramer

    The "Squawk on the Street" team weigh in on Pfizer's bid to takeover European drug maker AstraZeneca.

  • Hedge fund & big pharma pair up Wednesday, 23 Apr 2014 | 1:32 PM ET
    Hedge fund & big pharma pair up

    CNBC's Dominic Chu provides a timeline of Bill Ackman's stake in Allergan.

  • Carl Icahn's take on Ackman & Valeant Wednesday, 23 Apr 2014 | 9:19 AM ET
    Carl Icahn's take on Ackman & Valeant

    Activist investor Carl Icahn comments on Bill Ackman's role in the Valeant Pharmaceuticals bid for Allergan. The "Squawk on the Street" team provide insight.

  • Cramer: Can't lose if you're Ackman Wednesday, 23 Apr 2014 | 9:17 AM ET
    Cramer: Can't lose if you're Ackman

    The "Squawk on the Street" news team discuss the involvement of Bill Ackman in the deal between Valeant Pharmaceuticals and Allergan.

  • Ackman: Partnership with Valeant is not front running Wednesday, 23 Apr 2014 | 7:48 AM ET
    Ackman: Partnership with Valeant is not front running

    William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.

  • Ackman: Allergan clear fit for Valeant Wednesday, 23 Apr 2014 | 7:41 AM ET
    Ackman: Allergan clear fit for Valeant

    William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.

  • Valeant CEO: Deal will get done despite 'poison pill' Wednesday, 23 Apr 2014 | 7:37 AM ET
    Valeant CEO: Deal will get done despite 'poison pill'

    J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.

  • Valeant CEO: Allergan has a great set of assets Wednesday, 23 Apr 2014 | 7:33 AM ET
    Valeant CEO: Allergan has a great set of assets

    J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.

  • Ackman: Valeant fit into Pershing investing mold Wednesday, 23 Apr 2014 | 7:32 AM ET
    Ackman: Valeant fit into Pershing investing mold

    William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.

  • Einhorn's new course Tuesday, 22 Apr 2014 | 2:31 PM ET
    Einhorn's new course

    Sandy Villere, Villere Funds, shares his thoughts on Greenlight Capital's new stake in Conn's.

  • Pharma deal frenzy Tuesday, 22 Apr 2014 | 10:01 AM ET
    Pharma deal frenzy

    CNBC's Meg Tirrell digs into the friendly and hostile M&A action taking place in pharmaceuticals, including a deal between Novartis and GlaxoSmithKline, and Valeant Pharmaceuticals bid for Allergan.

  • Valeant's offer for Allergan Tuesday, 22 Apr 2014 | 8:03 AM ET
    Valeant's offer for Allergan

    Valeant Pharmaceuticals offered $48.30 share cash, as well as 0.83 shares for Allergan. CNBC's Meg Tirrell provides insight.

  • Ackman & Valeant's bid for Allergan Tuesday, 22 Apr 2014 | 7:04 AM ET
    Allergan shares jump on potential bid

    In an SEC Filing, Valeant Pharmaceuticals said it expected to offer a mix of stock and about $15 billion in cash for botox maker Allergan. David Krempa, Morningstar equity analyst, and CNBC's Meg Tirrell, provide perspective.

  • 'Poison Pill' inventor targets activism Friday, 28 Mar 2014 | 7:34 AM ET
    'Poison Pill' inventor targets activism

    Activism in the long-term is not only bad for shareholders but also bad for the economy as a whole, says Martin Lipton, Wachtell, Lipton, Rosen & Katz, expressing his views on shareholder activism. Also Lipton shares his thoughts on the two categories of hedge fund activism.

  • Go-shop process not a panacea: Expert Friday, 28 Mar 2014 | 6:53 AM ET
    Go-shop process not a panacea: Expert

    Eileen Nugent, Skadden, Arps, Slate, Meagher & Flom, and Robert Spatt, , Simpson Thacher & Bartlett, discuss go-shop deals in the M&A environment and the latest LBO buzz from New Orleans.

  • Zell: US economy is 'benign' Friday, 28 Feb 2014 | 8:16 AM ET
    Zell: US economy is 'benign'

    Sam Zell, Equity Group Investments chairman, shares his thoughts on the strength of the U.S. economy. We have to focus on growth, says Zell. James Bullard, Federal Reserve Bank of St. Louis president and CEO, weighs in.

  • Zell: CommonWealth REIT is flat as a dead man's EKG Friday, 28 Feb 2014 | 8:06 AM ET
    Zell: CommonWealth REIT is flat as a dead man's EKG

    Sam Zell, Equity Group Investments chairman, discusses backing an activist campaign to unseat the board and management of CommonWeath, a real estate investment trust that owns more than 300 office buildings.

  • Third Point makes move on Sotheby's Thursday, 27 Feb 2014 | 11:43 AM ET
    Third Point makes move on Sotheby's

    CNBC's Scott Wapner reports Dan Loeb's Third Point will nominate three members to Sotheby's board of directors including Loeb himself.